Celgene to Buy Abraxis Bioscience for $2.9 Billion
Celgene to Buy Abraxis Bioscience for $2.9 Billion
Celgene Corp., the maker of blood cancer drugs, agreed to buy Abraxis BioScience Inc. for $2.9 billion in cash and stock to acquire a solid-tumor medicine.
Read more on BusinessWeek
Categories: Breast Cancer Chemotherapy Tags: $2.9, Abraxis, Billion, Bioscience, Celgene
Celgene Acquires Abraxis for $2.9 Billion
Celgene Acquires Abraxis for $2.9 Billion
Celgene’s purchase expands the company into the solid tumor cancer drug market.
Read more on TheStreet.com